Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

Abstract Background Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression. Given that treatment requires commitment to long-term use, we evaluated the effects of tolvaptan discontinuation on the trajectory o...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Michael Lioudis, Xiaolei Zhou, Eric Davenport, Sasikiran Nunna, Holly B. Krasa, Dorothee Oberdhan, Ancilla W. Fernandes
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2023-06-01
Serie:	BMC Nephrology
Soggetti:	Autosomal dominant polycystic kidney disease (ADPKD) Tolvaptan Glomerular filtration rate Kidney volume Clinical trial Treatment
Accesso online:	https://doi.org/10.1186/s12882-023-03247-6
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!